Lazard上市基础设施主动型ETF GLIX 深 沪
等待开盘 10-08 09:30:00 美东时间
25.43
-0.068
-0.27%
华盛通- 最 高25.59
- 今 开25.59
- 成交量 1.30万股
- 最 低 25.33
- 昨 收 25.4979
- 总市值 4450.92万
- 52周最高 29.23
- 市盈率 静 --
- 换手率 0.74%
- 52周最低 24.7399
- 委 比 0.00%
- 总股本 175.03万
- 历史最高 30.47
- 量 比 0.70
- 振 幅 1.02%
- 历史最低 24.7399
- 每 手 1
- 风险率 1.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas
GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment.In a comprehensive pre-clinical program, orally administered GLIX1
05-19 19:04
BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas
The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announced in September 2025. The patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief
04-28 19:13
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma
An update from Bioline RX Ltd Sponsored ADR ( ($BLRX) ) is now available. BioLi...
03-26 19:28
BioLineRx Launches First Human Trial For Brain Cancer Drug
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase
03-26 19:17
